期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

司来吉兰治疗帕金森病新进展 被引量：11

Status and Progress of Selegiline in Treatment of Parkinson′s Disease
原文传递
导出
摘要 司来吉兰是一种选择性不可逆的单胺氧化酶B抑制剂,目前不仅作为帕金森病(PD)早期的一线治疗药物,而且作为PD晚期的辅助治疗药物被广泛运用。司来吉兰治疗PD具有独特的优势,能够改善早期PD的症状和体征,延缓其进程,保护神经元;对晚期PD辅助左旋多巴治疗也有较好的疗效。但其也有不良反应。本文介绍司来吉兰在临床应用的进展。 Selegiline is a selective irreversible monoamine oxidase type B（MAO-B） inhibitor, widely used in the treatment of Parkinson＇s disease（PD）. Selegiline is not only as the first-line treatment in the early PD, but also as adjuvant treatment in the advanced PD. The method of selegiline in treatment of PD has its unique advantages on improving signs and symptoms of PD, slowing the process of PD, and protecting neurons. In addition, selegiline has a good effect in supporting levodopa for advanced PD. However, there are some side effects. This paper will give a review on its clinical application.
作者 杨新玲 贾丛康 张晨 蒋雨平
机构地区 新疆医科大学第一附属医院神经医学中心 新疆医科大学公共卫生学院 复旦大学附属华山医院神经科
出处 《中国临床神经科学》 2008年第4期407-410,共4页 Chinese Journal of Clinical Neurosciences
关键词 司来吉兰 帕金森病 治疗 selegUine Parkinson＇s disease treatment
分类号 R742.5 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献25

  • 1Palhagen S, Heinonen E, Hagglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease[J]. Neurology, 2006,66:1200-1206
  • 2Goetz CG, Poewe W, Rascol O, et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 [J]. Mov Disord, 2005,20:523-539
  • 3Rubinstein TC. Giladi N, Hausdorff JM. The power of cueing to circumvent dopamine deficits: a review of physical therapy treatment of gait disturbances in Parkinson's disease[J]. Mov Disord, 2002,17:1148 -1160
  • 4赵武伟,何晓军,张致峰,孔令山,苏敬敬,谢惠君.司来吉兰对早期帕金森病患者多巴胺能神经元的影响(英文)[J].中国临床康复,2005,9(9):190-192. 被引量：4
  • 5Ebadi M, Sharma S, Shavali S,et al. Neuroprotective actions of selegiline[J].J Neurosci Res,2002,67:285
  • 6O, Kontkanen and E. Castren, Trophic effects of selegiline on cultured dopaminergic neurons[J]. Brain Res,1999,829:190-192
  • 7Youdim MB, Riederer PF. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson' s disease [J]. Neurology,2004,63:32 - 35
  • 8Palhagen S, Heinonen EH, Hagglund L et al. Selegiline delays the onset of disability in denovo parkinsonian patients. Swedish Parkinson Study Group[J]. Neurology,1998,51:520-525
  • 9Tetrud JW, Langston JW. The effect of deprenyl(selegiline) in the natural history of Parkinson' s disease[J].Science,1989,245:519-522
  • 10Ives N J, Stowe RL, Marro J, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3,525 patients[J]. BMJ,2004,329:593

二级参考文献34

  • 1Reichmann H. Neuroprotection in Parkinson disease. J Neurol 2002; 249:21 - 3.
  • 2Stocchi F,Olanow CW. Neuroprotection in Parkinson disease: clinical trials. J Ann Neurol 2003; 53(Suppl3): 87 - 97.
  • 3Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson disease. J Ann Neurol 2003;53:110 -9.
  • 4Staffen W,Mair A,Unterrainer J,et al. Measuring the progression of idiopathic Parkinson disease with [123Ⅰ]β-CIT SPECT. J Neural Transm 2000; 107:543 -52.
  • 5Winodrodzka A,Bergamns P,Booij J,et al. [123Ⅰ]β-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson disease. J Neural Transm 2001; 108:1011 -9.
  • 6Saji H,Iida Y. Biomedical imaging in pharmacology with nuclear medical imaging methodologies: positron emission tomography(PET) and single photon emission computed tomography (SPECT) . J Nippon Yakurigaku Zasshi 2003; 121 ( 3 ):181 -91.
  • 7Saji H,Iida Y,Kawashima H,et al. In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography. J Anal Sci 2003; 19(1): 67 -71.
  • 8Brucke T,Asenbaum S,Pirker W,et al. Quantification of the dopaminergic nerve cell loss in Parkinson disease quantified with[123Ⅰ] β-CIT and SPECT. J Cere Blood Flow Metab 1995; 15 (suppl 1 ): 37.
  • 9Clarke CE. A"cure" for Parkinson disease: can neuroprotection be proven with current trial designs? J Mov Disord 2004; 19(5): 491 -8.
  • 10Ebadi M,Sharma S,Shavali S,et al. Neuroprotective actions of selegiline. J Neurosci Res 2002; 67: 285 - 9.

共引文献14

同被引文献96

引证文献11

二级引证文献65

中国临床神经科学
2008年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部